Immunotherapy

Breast cancer is one of the world's most frequent and lethal tumours, accounting for a significant amount of cancer-related morbidity and fatality or death rate, particularly among women. Although initial stages of breast cancer may be curable, timely identification and suitable therapy are not routinely available. This discrepancy in healthcare access, particularly in low- and middle-income nations, has a continued influence on survival rates and quality of life. As our understanding of the biology associated with breast cancer grows, the illness is increasingly seen as a diverse set of diseases with discrete molecular subtypes, each with its own prognosis and treatment implications. This study provides a comprehensive overview of breast cancer, beginning with its pathophysiology and categorization systems and proceeding through the landscape of both traditional and innovative therapeutic options. Surgery, chemotherapy, and radiation therapy remain standard treatments, but recent breakthroughs have extended therapeutic choices with the advent of targeted medications. Therapies including HER2 inhibitors, CDK4/6 inhibitors, PARP inhibitors, and immune checkpoint inhibitors have considerably improved clinical outcomes in some patient groups. Furthermore, hormonal medicines and gene-based treatments are evolving, enabling more personalized and effective care regimens. This article seeks to provide a comprehensive overview of how breast cancer is being handled and where it is going by investigating both existing therapies and the most recent advances in care.